Pharmaceutical composition

A pharmaceutical composition, comprising:

• (A) a tricyclic compound of Formula (I) or a pharmaceutically acceptable salt of (A):
• wherein
• each of adjacent pairs of R1 and R2, R3 and R4 or R5 and R6 independently
• (a) are two adjacent hydrogen atoms, or
• (b) may form another bond between the carbon atoms to which they are attached;
• R2 is an alkyl group;
• R7 is a hydrogen atom, a hydroxy group, a protected hydroxy group or alkoxy group, or an oxo group together with R1;
• each of R8 and R9 is independently a hydrogen atom or a hydroxy group;
• R10 is a hydrogen atom, an alkyl group, an alkyl group substituted by one or more hydroxy groups, an alkenyl group, an alkenyl group substituted by one or more hydroxy groups, or an alkyl group substituted by an oxo group;
• X is an oxo group, (a hydrogen atom and a hydroxy group), two hydrogen atoms, or a group of formula -CH2O-;
• Y is an oxo group, (a hydrogen atom and a hydroxy group), two hydrogen atoms, or a group of formulas N—NR11R12 or N—OR13;
• each of R11 and R12 is independently a hydrogen atom, an alkyl group, an aryl group or a tosyl group;
• each of R13, R14, R15, R16, R17, R18, R19, R22 and R23 is independently a hyd or an alkyl group;
• each of R20 and R21 is independently an oxo group, (R20a and a hydrogen atom), or (R21a and a hydrogen atom);
• wherein each of R20a and R21a is independently a hydroxy group, an alkoxy group or a group of formula —OCH2OCH2CH2OCH3, or R21a is a protected hydroxy group, or R20a and R21a both represent an oxygen atom in an epoxide ring;
• n is an integer of 1 or 2;
• and
• Y, R10 and R23, together with the carbon atoms to which they are attached, may represent a saturated or unsaturated 5- or 6-membered nitrogen, sulfur and/or oxygen containing heterocyclic ring optionally substituted by at least one group selected from the group consisting of an alkyl, a hydroxy, an alkyl substituted by at least one hydroxy group, an alkoxy, a benzyl and a group of the formula —CH2Se(C6H5);
• (B) an oil substance combination of isopropyl myristate and diethyl sebacate;
• (C) a surfactant which is selected from the group consisting of a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a pentaglycerol fatty acid ester and a glycerol fatty acid ester;
• (D) a hydrophilic substance which is capable of imparting viscosity to liquids;
• (E) water;
• and
• (F) optionally a pH control agent.